November is COPD Awareness Month, endobronchial valves, a revolutionary minimally invasive treatment, are giving patients a ...

Background Valvular heart disease (VHD) represents a significant burden on healthcare systems worldwide, necessitating ...

The global heart valve devices market size was valued at over USD 10 billion in 2023 and experiencing a significant CAGR of ...

Chest CTA revealed a 4.6 cm x 2.5 cm right ventricular mass, multiple pulmonary nodules, and bilateral pulmonary emboli. Transesophageal echocardiogram identified a large irregularly bordered mass ...

Patients who receive pulmonary artery catheters (PACs) after cardiac surgery have significantly reduced risk for 1-year mortality.

Authors of a recent review shared expert insights and tips for conducting cardiac catheterization procedures to diagnose ...

Background: Among 40,000 newborns with congenital heart defects, many face right ventricular outflow tract (RVOT) dysfunction, requiring pulmonary valve replacement. Existing options like the Melody™ ...

Surgical interventions on the pulmonary valve in adults have been increasing over the years, as patients with congenital heart diseases are experiencing extended lifespans. Reoperations involving ...

About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr ® Endobronchial ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.